Pharma Fridays — March 7, 2025

March 7, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Celltrion Receives U.S. FDA Approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Biosimilars Referencing PROLIA® and XGEVA® On March 3, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Pharma Fridays

←Weighing In: Making Obesity Treatment More Effective and Accessible by 2030

Kids On the Move: Protecting Future Generations from Obesity→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today